Gerald Pierone Jr., M.D.

Gerald Pierone Jr., M.D.

Atripla (which is a combination of efavirenz + tenofovir + emtricitabine) is the acknowledged king in the realm of first-line antiretroviral therapy. Le Roi est mort, vive le Roi! Not so fast: The king still breathes. But ...

Gerald Pierone Jr., M.D.

While scanning the CROI 2010 abstracts during my six-hour plane ride to San Francisco, the thought occurred to me that we may be witnessing the winding down of the HIV drug development process.

This is Gerald Pierone from the AIDS Research and Treatment Center of the Treasure Coast. I'm here in Mexico City at the International AIDS Conference with Dr. Ben Young, and we're at a poster presentation. The title of the poster is "Switching to Fo...

Although atazanavir, also known as Reyataz, is not uncommonly used in first-line patients, it is not officially approved by the U.S. Food and Drug Administration [FDA] for such use. In a large study presented at CROI 2008, atazanavir was compared w...

There's nothing like hearing the results of studies directly from those who actually conducted the research. It is these women and men who are transforming HIV treatment and care. In this interview, you'll meet one of these impressive HIV researchers...

There's nothing like hearing the results of studies directly from those who actually conducted the research. It is these women and men who are transforming HIV treatment and care. In this interview, you'll meet one of these impressive HIV researchers...

There's nothing like hearing the results of studies directly from those who actually conducted the research. It is these women and men who are transforming HIV treatment and care. In this interview, you'll meet one of these impressive HIV researchers...

There's nothing like hearing the results of studies directly from those who actually conducted the research. It is these women and men who are transforming HIV treatment and care. In this interview, you'll meet one of these impressive HIV researchers...

There's nothing like hearing the results of studies directly from those who actually conducted the research. It is these women and men who are transforming HIV treatment and care. In this interview, you'll meet one of these impressive HIV researchers...

There's nothing like hearing the results of studies directly from those who actually conducted the research. It is these women and men who are transforming HIV treatment and care. In this interview, you'll meet one of these impressive HIV researchers...

Background

There are many HIV-infected patients who have multi-drug resistant virus and/or medication intolerances and thus are faced with limited treatment options. Tipranavir (TPV, Aptivus) was approved in June 2005 for patients in need of new ant...

Background

One of the fundamental tenets of HIV patient education is that a very high level of adherence to antiretroviral therapy is essential to achieve an optimal treatment outcome. This innovative pilot study of a 5-day-on, 2-day-off (FOTO) ther...